Key Highlights

  • Addus HomeCare (NASDAQ:ADUS) lifted adjusted Net Income per diluted share 17.3% to USD 1.83 in the third quarter, while net service revenues rose 7.0% to USD 387.7 million.
  • At September 30, 2026, InnovAge (NASDAQ:INNV) had roughly 8,420 enrolled participants across 20 centers, with care costs taking close to 76% of revenue.
  • Fresenius Medical Care (NYSE:FMS) saw Operating Income before special items slide 6% at constant currency, and its 2026 outlook now sits in the lower half of earlier guidance.
  • Ceribell (NASDAQ:CBLL) ended September with USD 117.5 million in cash and marketable securities, while its accumulated Deficit reached USD 280.7 million.

Addus HomeCare (NASDAQ:ADUS): Operating Leverage Lifts Adjusted Earnings

Addus HomeCare (NASDAQ:ADUS) announced third quarter 2026 results on November 3, 2026, for the quarter ended September 30. Net service revenues increased 7.0% to USD 387.7 million, while GAAP net income reached USD 28.6 million, or USD 1.54 per diluted share. On an adjusted basis, Earnings per diluted share rose 17.3% to USD 1.83 from USD 1.56. Gross Margin held roughly steady at 32.1%, so the faster profit growth reflects general and administrative costs rising only about 1.4% against 7.0% Revenue growth, by simple arithmetic on reported figures. Interest cost on borrowings shrank to USD 0.7 million, down from USD 2.6 million. Personal care accounted for 77.6% of revenue, aided by the first full quarter from the HomeCourt Home Care acquisition. On September 14, 2026, the company agreed to acquire AccentCare's personal care division for about USD 275.0 million, a deal expected to add roughly USD 280 million of annualized revenue and still subject to regulatory approvals. Hospice made up 17.8% of revenue. The company closed September with USD 98.5 million of cash against USD 24.3 million of bank debt, and the material gave no formal guidance.

InnovAge (NASDAQ:INNV): Colorado Rate Cuts and Paused Expansion in Two States

InnovAge (NASDAQ:INNV) disclosed the three-month results ending September 30, 2026 in a November 3, 2026 filing. The company operates Programs of All-Inclusive Care for the Elderly, a model in which it takes full financial responsibility for frail seniors' medical care in exchange for a fixed monthly payment from Medicare and Medicaid. Roughly 76% of revenue went to external provider costs and cost of care. Revenue, net income and cash figures were absent from the extract, so none are reported here. Management expects margins to face pressure during fiscal 2027, partly because Colorado Medicaid premium rates are being reduced retroactively from July 1, 2026. California and Colorado have each halted new PACE applications and service area expansions, with pauses lasting until at least November 19, 2027 and October 31, 2028. A corrective action plan in California is still underway, and a Downey application was pulled back in July 2026. Members leaving voluntarily have averaged 6.5% annually across three fiscal years. Slower Medicaid eligibility decisions could weigh on enrollment, although management said that has not yet had a material effect. Heavier spending on technology and artificial intelligence adds to near-term costs as a share of revenue.

Fresenius Medical Care (NYSE:FMS): A New CEO Lowers the Profit Outlook

Fresenius Medical Care (NYSE:FMS) held its third quarter 2026 call on November 3, 2026, the first led by Shervin Korangy, who had taken over as chief executive three weeks earlier. Operating income before special items declined 6% at constant currency, leaving an Operating Margin of 11%. Management now sees 2026 operating income moving flat to down by a mid-single-digit amount, which lands in the lower half of the earlier guidance. TDAPA, a temporary Medicare add-on for newly approved dialysis drugs, has turned from a tailwind into a headwind, and the pressure is expected to intensify in the fourth quarter. Inflation is forecast to run above the top of the original EUR 300 million range. Special items reduced results by a net EUR 161 million. Recent FDA audits at company facilities triggered corrective and preventive actions, a regulatory exposure the call did not quantify. By September 30 the company had used EUR 357 million of its second EUR 1 billion share repurchase program. Net leverage remained at 2.6 times, and Operating Cash Flow climbed 8%. No cover page confirmed the exchange listing, and the numbers here come from remarks management made aloud.

Ceribell (NASDAQ:CBLL): Cash Reserves Support a Growing Hospital Footprint

Ceribell (NASDAQ:CBLL) produced its quarterly filing on November 3, 2026, for the period ended September 30. The medical technology Business offers a point-of-care electroencephalogram system built from disposable headbands, a pocket-sized recorder and AI-driven algorithms that flag seizures and delirium in acute care settings. More than 700 hospitals have adopted the platform, while the company points to around 6,000 acute care facilities across the United States that could benefit. Cash and marketable securities totaled USD 117.5 million, and management believes that amount covers at least the next 12 months, although the estimate depends on assumptions that could prove wrong. The company anticipates ongoing operating losses and could need to raise additional capital. Clearances from the agency were granted in December 2025, then June 2026, then September 2026. Sales come through single-use Wearables and monthly subscription fees, and summer usually brings fewer intensive care admissions. Contract factories in China and Vietnam produce the headbands, so tariffs and shipping costs feed into cost of revenue. The extract omitted quarterly revenue and net loss, and it offered no trading Volume data, so thin-trading risk could not be evaluated.

Where Things Stand

Adjusted EPS at Addus rose 17.3% because overhead grew more slowly than revenue, interest costs fell and an Acquisition contributed a full quarter, while gross margin barely moved. Addus HomeCare (NASDAQ:ADUS) also carries modest bank Debt ahead of its pending USD 275.0 million purchase of AccentCare's personal care division. InnovAge (NASDAQ:INNV) faces expected Colorado rate reductions and two state expansion pauses, and the extract lacked its revenue and profit. Fresenius Medical Care (NYSE:FMS) narrowed its 2026 outlook as TDAPA support fades and inflation rises. Ceribell (NASDAQ:CBLL) offered cash and hospital uptake data, though no revenue or loss totals. Results point in mixed directions, with pressures falling unevenly. Watch Addus's AccentCare approval, InnovAge's California corrective plan, Fresenius's next outlook update and Ceribell's full financial statements.